Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,039Revenue (TTM) $M178Net Margin (%)-76.9Altman Z-Score0.4
Enterprise Value $M965EPS (TTM) $-3.4Operating Margin %-69.7Piotroski F-Score4
P/E(ttm)--Beneish M-Score2.7Pre-tax Margin (%)-77.1Higher ROA y-yY
Price/Book13.310-y EBITDA Growth Rate %--Quick Ratio4.4Cash flow > EarningsN
Price/Sales5.75-y EBITDA Growth Rate %--Current Ratio4.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-63.6Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-14,620.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M51.3ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with CHRS

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

CHRS is held by these investors:



CHRS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Herman Alan C.Chief Scientific Officer 2017-05-01Sell11,333$201.25view
Herman Alan C.Chief Scientific Officer 2017-04-03Sell11,333$20.73-2.32view
Herman Alan C.Chief Scientific Officer 2017-03-01Sell11,333$24.19-16.29view
Herman Alan C.Chief Scientific Officer 2017-02-01Sell11,333$27.37-26.01view
Viret Jean-FredericCFO 2017-01-25Sell3,900$27-25view
Herman Alan C.Chief Scientific Officer 2017-01-03Sell11,333$27.95-27.55view
Viret Jean-FredericCFO 2016-12-16Sell3,900$28.3-28.45view
Wahlstrom MatsDirector 2016-12-08Sell53,583$27.52-26.42view
Herman Alan C.Chief Scientific Officer 2016-12-01Sell11,333$27.4-26.09view
Viret Jean-FredericCFO 2016-11-18Sell3,900$28.19-28.17view

Press Releases about CHRS :

Quarterly/Annual Reports about CHRS:

News about CHRS:

Articles On GuruFocus.com
AbbVie's Humira Loses Patent in Coherus’ Petitions May 18 2017 
Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results May 08 2017 
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in May May 01 2017 
Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar Apr 25 2017 
Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th Apr 24 2017 
Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development Mar 27 2017 
Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Res Mar 13 2017 
Coherus Addresses Trade Secret Action Filed by Amgen Mar 06 2017 
Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint Mar 02 2017 
Statement by Coherus CEO Regarding Biosimilars User Fees Mar 02 2017 

More From Other Websites
[$$] AbbVie: It's the Pipeline, Not the Coherus Ruling May 18 2017
AbbVie Down on Humira Patent Loss: Is More Damage in Store? May 18 2017
AbbVie Loses Key Humira Patent In Battle With Small-Cap Biotech May 17 2017
Why This Humira Patent Loss Might Not Be What You Think May 17 2017
AbbVie Stock Lower on Humira Patent Ruling May 17 2017
Coherus BioSciences Prevails in ‘135 IPR Decision May 16 2017
Edited Transcript of CHRS earnings conference call or presentation 8-May-17 8:30pm GMT May 13 2017
Coherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : May 12, 2017 May 12 2017
Are Options Traders Betting on a Big Move in COHERUS BIOSCIENCES (CHRS) Stock? May 12 2017
Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : May 11,... May 11 2017
Coherus BioSciences reports 1Q loss May 08 2017
Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results May 08 2017
Investor Network: Coherus BioSciences, Inc. to Host Earnings Call May 08 2017
The Prospects For CHS-3351, Coherus' Most Underappreciated Asset May 05 2017
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in May May 01 2017
ETFs with exposure to Coherus BioSciences, Inc. : April 25, 2017 Apr 25 2017
Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar Apr 25 2017
Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th Apr 24 2017
Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development Mar 27 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)